ADVFN US – Market Content Editor
-
U.S. Stocks See Further Downside As Early Buying Interest Evaporates
Following the sell-off seen during Thursday’s session, stocks rebounded in early trading on Friday but showed a notable move back to the downside as the day progressed. The major averages pulled back well off their early highs and into negative territory. The major averages added to the steep losses posted in the previous session, falling…
-
Oil demand destruction likely only at around $155/bbl, Bernstein says
Oil prices would have to climb significantly above current levels before triggering a meaningful drop in demand, according to analysis from Bernstein. Analyst Irene Himona said that “in today’s money we would need $155/bbl as the FY26 annual average, to reach the same 5.2% oil burden” experienced in 2007, a level historically associated with high…
-
Foresight Autonomous Holdings : Eye-Net Collision Prevention Technology Shows Positive Results in Bordeaux Transit Trial
Foresight Autonomous Holdings Ltd. (NASDAQ:FRSX) said its majority-owned subsidiary Eye-Net Mobile Ltd. has successfully completed a large-scale live pilot of a smart mobility safety project in Bordeaux, France, conducted in collaboration with Renault Group, Orange S.A., and other partners. The project, known as SafeCycloMove, tested Eye-Net’s collision-prevention technology in a real-world public transportation environment involving…
-
Acurx Pharmaceuticals Reports Stronger Cash Position and Clinical Progress in Q4 2025
Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position and continued progress in the development of its lead antibiotic candidate, ibezapolstat, for the treatment of Clostridioides difficile infection (C. difficile). The company said its cash balance more than doubled year over year, reaching $7.6 million as of December 31, 2025,…
-
Aditxt Acquires Ignite Proteomics to Expand Precision Oncology Capabilities
Aditxt Inc. (NASDAQ:ADTX) announced it has acquired Ignite Proteomics LLC, a precision oncology company specializing in functional proteomics technology used to guide cancer treatment decisions, according to a company press release. The deal assigns Ignite a stated value of $36 million, with Aditxt issuing 36,000 shares of newly created Series A-2 Convertible Preferred Stock as…
-
Innovation Beverage Prices $6M Public Offering at $1.75 Per Unit
Innovation Beverage Group Limited (NASDAQ:IBG) announced the pricing of a public offering expected to raise approximately $6 million in gross proceeds before fees and expenses, according to a company press release. The offering includes 3,428,569 units priced at $1.75 each. Each unit consists of one ordinary share or one pre-funded warrant, along with one Series…
-
Immutep Shares Collapse After Lung Cancer Trial Halted for Futility
Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would discontinue its Phase III TACTI-004 clinical trial following a futility review. The Independent Data Monitoring Committee (IDMC) recommended ending the study, which was evaluating eftilagimod alfa (“efti”) as a treatment for patients with first-line non-small cell lung cancer. After…
-
DevvStream Cuts $5.9M in Debt Through Equity Conversions and New Financing Support
DevvStream Corp. (NASDAQ:DEVS) said Thursday it has completed a series of transactions that reduce its outstanding debt by approximately $5.9 million, according to a company press release. The move comes as the company works to address liquidity pressures, with its current ratio standing at 0.12 for the trailing twelve months ending Q1 2026. As part…
-
bioAffinity Technologies Posts 2025 Results as CyPath Lung Testing Growth Accelerates
bioAffinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a statement issued Friday. The biotechnology company reported revenue of $6.2 million in 2025, representing a 34% decline from $9.4 million in 2024. The decrease was largely attributed to the company’s decision to discontinue certain unprofitable pathology services…
-
ParaZero Secures New Israeli Defense Order for DefendAir Counter-Drone Technology
On March 13, 2026, ParaZero Technologies (NASDAQ:PRZO) revealed it had received a new purchase order from an Israeli defense organization for its DefendAir Counter-Unmanned Aerial Systems platform. The order covers the supply of an evaluation package that includes DefendAir net pods, as well as operational exercises and training sessions aimed at speeding up deployment and…